Compare BSET & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSET | MDXH |
|---|---|---|
| Founded | 1902 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Home Furnishings | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.2M | 183.4M |
| IPO Year | 1995 | 2021 |
| Metric | BSET | MDXH |
|---|---|---|
| Price | $14.00 | $3.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.67 |
| AVG Volume (30 Days) | 23.2K | ★ 110.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | ★ 163.06 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $456,855,000.00 | N/A |
| Revenue This Year | $4.63 | $30.31 |
| Revenue Next Year | $4.34 | $18.38 |
| P/E Ratio | $20.00 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.96 | $1.36 |
| 52 Week High | $19.75 | $5.33 |
| Indicator | BSET | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 36.16 | 42.88 |
| Support Level | N/A | $3.05 |
| Resistance Level | $17.29 | $3.78 |
| Average True Range (ATR) | 0.50 | 0.17 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 26.17 | 15.09 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.